Trials / Recruiting
RecruitingNCT06922357
A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors
A Phase I/II, Open-label, Multi-centre Study Evaluating the Safety,Tolerability,Pharmacokinetic (PK), Pharmacodynamics, and Preliminary Efficacy of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors With MTAP Deficiency
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy characteristics of HRS-6719 in patients with MTAP-deficient advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-6719 | HRS-6719 |
Timeline
- Start date
- 2025-04-24
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2025-04-10
- Last updated
- 2025-05-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06922357. Inclusion in this directory is not an endorsement.